Real-World Treatment Outcomes of an Artificial Tear Containing Arabinogalactan, Hyaluronic Acid and Trehalose Among Subjects with Dry Eye

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Date 2025 Jan 13

PMID 39801568

Authors

Andrea Bedei

Pedro Rocha Cabrera

Luis Oliveira

Laura Castellini

Giulia De Grazia

Stefano Remiddi

Affiliations

Soon will be listed here.

Abstract

Purpose: To assess the efficacy, adherence, and tolerability of a new artificial tear based on arabinogalactan, hyaluronic acid, and trehalose in a population with dry eye disease (DED).

Methods: A retrospective, real-world, post-marketing study identified 96 adult patients (aged 18-80 years) with signs and symptoms of dry eye. These patients received fixed combination therapy with eye drops containing arabinogalactan, hyaluronic acid, and trehalose at various dosing schedules. The data for this study were collected from April 2022 to June 2023. Patients underwent evaluation at baseline (T0) and after a follow-up period of two-three months (T1) using a patient-reported questionnaire.

Results: In 96 adult patients (71 women and 25 men) with dry eye due to various conditions, the results indicated a 98% positive response to therapy. This response included improvements in vision (13%), comfort (39%), redness (13%), itching (16%), photophobia (4%), and tearing (14%). Additionally, 61% of the patients experienced 1-2 hours of comfort following instillation.

Conclusion: This real-life post-marketing study demonstrated clinical improvement of signs and symptoms in patients with dry eye disease using a new artificial tear medical device based on arabinogalactan, hyaluronic acid, and trehalose.

References

Yang Y, Lee W, Kim Y, Hong Y . A Meta-Analysis of the Efficacy of Hyaluronic Acid Eye Drops for the Treatment of Dry Eye Syndrome. Int J Environ Res Public Health. 2021; 18(5). PMC: 7967738. DOI: 10.3390/ijerph18052383. View

Battelli M, Bolognesi A, Polito L . Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. Biochim Biophys Acta. 2014; 1842(9):1502-17. DOI: 10.1016/j.bbadis.2014.05.022. View

Stuart J, Linn J . Dilute sodium hyaluronate (Healon) in the treatment of ocular surface disorders. Ann Ophthalmol. 1985; 17(3):190-2. View

Pflugfelder S, Jones D, Ji Z, Afonso A, Monroy D . Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999; 19(3):201-11. DOI: 10.1076/ceyr.19.3.201.5309. View

Badnjevic A, Gurbeta Pokvic L, Deumic A, Becirovic L . Post-market surveillance of medical devices: A review. Technol Health Care. 2022; 30(6):1315-1329. DOI: 10.3233/THC-220284. View

Wolffsohn J, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K . TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017; 15(3):539-574. DOI: 10.1016/j.jtos.2017.05.001. View

Baudouin C, Irkec M, Messmer E, Benitez-Del-Castillo J, Bonini S, Figueiredo F . Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting. Acta Ophthalmol. 2017; 96(2):111-119. PMC: 5836968. DOI: 10.1111/aos.13436. View

Burgalassi S, Nicosia N, Monti D, Falcone G, Boldrini E, Fabiani O . Arabinogalactan as active compound in the management of corneal wounds: in vitro toxicity and in vivo investigations on rabbits. Curr Eye Res. 2010; 36(1):21-8. PMC: 3154582. DOI: 10.3109/02713683.2010.523193. View

Messmer E, von Lindenfels V, Garbe A, Kampik A . Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. Ophthalmology. 2016; 123(11):2300-2308. DOI: 10.1016/j.ophtha.2016.07.028. View

10.

Reyes-Batlle M, Rodriguez-Talavera I, Sifaoui I, Rodriguez-Exposito R, Rocha-Cabrera P, Pinero J . In vitro amoebicidal effects of arabinogalactan-based ophthalmic solution. Int J Parasitol Drugs Drug Resist. 2021; 16:9-16. PMC: 8099451. DOI: 10.1016/j.ijpddr.2021.04.005. View

11.

Moschini R, Gini F, Cappiello M, Balestri F, Falcone G, Boldrini E . Interaction of arabinogalactan with mucins. Int J Biol Macromol. 2014; 67:446-51. DOI: 10.1016/j.ijbiomac.2014.04.001. View

12.

Smith R . The tear film complex: pathogenesis and emerging therapies for dry eyes. Cornea. 2004; 24(1):1-7. DOI: 10.1097/01.ico.0000141486.56931.9b. View

13.

Chandrasekaran R, Janaswamy S . Morphology of Western larch arabinogalactan. Carbohydr Res. 2002; 337(21-23):2211-22. DOI: 10.1016/s0008-6215(02)00223-9. View

14.

Elieh Ali Komi D, Rambasek T, Bielory L . Clinical implications of mast cell involvement in allergic conjunctivitis. Allergy. 2017; 73(3):528-539. DOI: 10.1111/all.13334. View

15.

Dion C, Chappuis E, Ripoll C . Does larch arabinogalactan enhance immune function? A review of mechanistic and clinical trials. Nutr Metab (Lond). 2016; 13:28. PMC: 4828828. DOI: 10.1186/s12986-016-0086-x. View

16.

Panigrahi T, Shivakumar S, Shetty R, DSouza S, Nelson E, Sethu S . Trehalose augments autophagy to mitigate stress induced inflammation in human corneal cells. Ocul Surf. 2019; 17(4):699-713. DOI: 10.1016/j.jtos.2019.08.004. View

17.

Johnson M, Murphy P, Boulton M . Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye. Graefes Arch Clin Exp Ophthalmol. 2005; 244(1):109-12. DOI: 10.1007/s00417-005-0028-1. View

18.

Pinto-Fraga J, Enriquez-de-Salamanca A, Calonge M, Gonzalez-Garcia M, Lopez-Miguel A, Lopez-de la Rosa A . Severity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a phase III clinical trial. Ocul Surf. 2018; 16(3):368-376. DOI: 10.1016/j.jtos.2018.05.001. View

19.

Sullivan D, Rocha E, Aragona P, Clayton J, Ding J, Golebiowski B . TFOS DEWS II Sex, Gender, and Hormones Report. Ocul Surf. 2017; 15(3):284-333. DOI: 10.1016/j.jtos.2017.04.001. View

20.

Burgalassi S, Nicosia N, Monti D, Falcone G, Boldrini E, Chetoni P . Larch arabinogalactan for dry eye protection and treatment of corneal lesions: investigations in rabbits. J Ocul Pharmacol Ther. 2007; 23(6):541-50. DOI: 10.1089/jop.2007.0048. View